Integrated analysis of recombinant BPV-1 L1 protein for the production of a bovine papillomavirus VLP vaccine

Publication date: 14 March 2017
Source:Vaccine, Volume 35, Issue 12
Author(s): Diego Grando Módolo, Rodrigo Pinheiro Araldi, Jacqueline Mazzuchelli-de-Souza, Alexandre Pereira, Daniel Carvalho Pimenta, Letícia Maria Zanphorlin, Willy Beçak, Marcelo Menossi, Rita de Cassia Stocco, Rodrigo Franco de Carvalho
Bovine papillomatosis is an infectious disease that is caused by bovine papillomavirus (BPV), which results in important economic losses. However, no BPV vaccines or effective treatment methods are commercially available to date. Moreover, the absence of papillomavirus replication in vitro makes the use of recombinant protein a promising candidate for vaccine formulations. Hence, we developed an integrated study on the L1 capsid protein of BPV-1, obtained from a bacterial expression system, regarding its purification, biosafety, thermostability and immunogenicity. The results indicated an absence of genotoxicity of the purified recombinant L1 protein, β-sheet prevalence of secondary structure folding, protein stability under high temperatures as well as the presence of capsomeres and VLPs. In addition, preliminary experimental vaccination of calves showed the production of specific antibodies against BPV-1 L1.



http://ift.tt/2lTr97w